A Phase I Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) With Radiation in Patients With Metastatic Sarcoma

Next Previous
Trial Profile

A Phase I Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) With Radiation in Patients With Metastatic Sarcoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Glycopyranosyl lipid adjuvant (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions

    • Most Recent Events

    • 17 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
    • 05 Apr 2017 Results assessing effect of intratumoral injection of G100 on systemic anti-tumor immune response in the soft tissue sarcoma microenvironment, presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 23 Jan 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top